Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. It reduces renal glucose reabsorption by selectively inhibiting the sodium glucose cotransporter 2 in the proximal renal tubule, producing increased urinary glucose excretion and lowering plasma glucose independently of insulin secretion. The molecule is administered orally and supports once daily dosing; typical starting dose used in clinical practice is 2.5 mg once daily with escalation to 5 mg when indicated. Pharmacokinetic characteristics include rapid oral absorption with time to peak concentration commonly within 0.5 to 2 hours and an elimination half life that supports once daily administration. Metabolism is primarily hepatic with renal and fecal excretion of parent and metabolites, and protein binding is moderate to high. In a meta-analysis involving data from 10 randomized controlled trials (1304 patients) luseogliflozin demonstrated consistent reductions in HbA1c and fasting plasma glucose versus placebo, with attendant reductions in body weight and modest reductions in systolic blood pressure; safety signals were consistent with the SGLT2 inhibitor class including increased risk of genital mycotic infections and volume depletion in susceptible patients. Clinical use is as monotherapy or in combination with other oral antidiabetic agents or insulin as guided by local regulatory labeling and clinical judgment.
Parent: Luseogliflozin
For active pharmaceutical ingredient production and regulatory submissions, luseogliflozin is characterized by a defined impurity profile and specification limits consistent with ICH Q3A and Q3B principles. Typical API specifications include assay acceptance in the high purity range, for example 98.0 to 102.0 percent on a dry basis, individual unspecified impurities controlled to not more than 0.10 percent, specified related substances controlled to not more than 0.20 percent each, and total impurities limited to 0.50 to 1.0 percent depending on the dossier and product form. Related compounds typically observed and monitored by HPLC and LC MS include process-related intermediates, positional isomers, minor oxidative and hydrolytic degradants, and desoxy or hydroxylated analogs; these are assigned impurity identifiers such as Impurity A, Impurity B and so on in analytical reports. Residual solvents are limited according to ICH Q3C and are tested by gas chromatography, and elemental impurities are controlled per ICH Q3D. Routine control methods include stability-indicating reversed phase HPLC with UV detection, orthogonal confirmation by LC MS, and targeted quantitative assays for specified impurities.
Luseogliflozin is indicated for the management of type 2 diabetes mellitus; it lowers blood glucose by inhibiting renal SGLT2 leading to increased urinary glucose excretion and is used as monotherapy or in combination with other glucose lowering therapies according to the approved label.
Luseogliflozin is dosed once daily and is generally taken in the morning; it may be taken with or without food, but patients should follow the prescribing information and their healthcare provider guidance for timing and any dose adjustments.
